Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.700
0.00 (0.00%)
At close: Mar 19, 2026, 4:00 PM EDT
1.620
-0.080 (-4.71%)
Pre-market: Mar 20, 2026, 9:13 AM EDT

Milestone Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.55-1515
Revenue Growth (YoY)
---80.00%-66.67%-
Gross Profit
1.55-1515
Selling, General & Admin
45.5827.7531.0524.8119.4
Research & Development
18.1114.3631.0539.8338.67
Operating Expenses
63.6942.162.164.6458.07
Operating Income
-62.14-42.1-61.1-59.64-43.07
Interest Expense
-3.84-3.58-2.55--
Interest & Investment Income
2.924.163.971.250.22
Pretax Income
-63.06-41.52-59.69-58.39-42.85
Net Income
-63.06-41.52-59.69-58.39-42.85
Net Income to Common
-63.06-41.52-59.69-58.39-42.85
Shares Outstanding (Basic)
8462434242
Shares Outstanding (Diluted)
8462434242
Shares Change (YoY)
34.84%44.82%1.19%1.47%42.56%
EPS (Basic)
-0.75-0.67-1.39-1.38-1.02
EPS (Diluted)
-0.75-0.67-1.39-1.38-1.02
Free Cash Flow
-49.34-28.88-46.54-52.74-33.22
Free Cash Flow Per Share
-0.59-0.46-1.08-1.24-0.79
Gross Margin
100.00%-100.00%100.00%100.00%
Operating Margin
-4019.40%--6109.80%-1192.84%-287.15%
Profit Margin
-4078.78%--5968.50%-1167.76%-285.69%
Free Cash Flow Margin
-3191.66%--4653.60%-1054.82%-221.49%
EBITDA
-62.03-42-61.01-59.55-42.98
EBITDA Margin
-----286.53%
D&A For EBITDA
0.110.110.090.090.09
EBIT
-62.14-42.1-61.1-59.64-43.07
EBIT Margin
-----287.15%
Updated Mar 20, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q